Prescient Reveals PTX-100 Phase 1b Study Results in T-Cell Lymphoma
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study...
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study...
Prescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCallum Cancer Centre...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.